Advertisement

The neurotoxic component in Parkinson’s disease may involve iron-melanin interaction and lipid peroxidation in the substantia nigra

  • M. B. H. Youdim
  • D. Ben-Shachar
Part of the New Vistas in Drug Research book series (DRUG RESEARCH, volume 1)

Summary

There are indications of oxidative stress in Parkinson’s disease (PD). This can be attributed to the selective increases of iron (III) due to its decompartmentalization and lipid peroxidation and a decrease of glutathione (GSH) oxidation in substantia nigra (SN). The net effect would be accumulation of H2O2, and the formation of free cytotoxic hydroxyl (OH·) radical from the interaction of iron either with H2O2 or melanin or both, to drive the Fenton reaction. Identification of two high-affinity binding sites for Fe3+ on dopamine-melanin indicates the iron binding potency of melanin. This interaction does not result in prevention but rather in potentiation of iron-induced lipid peroxidation, a process selectively inhibited by iron chelators. Thus, H2O2 and melanin are thought to participate in altering the redox state of iron between its two valencies with resultant formation of OH·. This hypothesis can explain the vulnerability and selectivity of melaninized nigrostriatal dopamine neurons to degeneration in PD. Determination of OH· or lipofusin in the CSF, as a by-product of lipid peroxidation, may be a valid approach to early diagnosis of PD.

Keywords

Lipid Peroxidation Substantia Nigra Iron Overload Oxygen Free Radical Iron Chelator 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Alexander P (1960) Protection of macromolecules in vitro against damage by ionizing radiation. In: Hollander A (ed) Radiation protection and recovery. Pergamon Press, New YorkGoogle Scholar
  2. Barker R (1989) Environmental toxins and Parkinson’s disease. Trends Neurosci 12: 182CrossRefGoogle Scholar
  3. Ben Shachar D, Ashkenazi R, Youdim MBH (1986) Long-term consequences of early iron deficiency on dopaminergic neurotransmission in rats. Int J Dev Neurosci 4: 81–88CrossRefGoogle Scholar
  4. Ben Shachar D, Riederer P, Youdim MBH (1989) Iron-melanin interaction in the substantia nigra as the neurotoxic component of Parkinson’s disease (submitted)Google Scholar
  5. Braughler JM, Duncan LA, Chase RL (1986) The involvement of iron in lipid peroxidation importance of ferric to ferrous ratio in initiation. J Biol Chem 261: 10282–10289PubMedGoogle Scholar
  6. Braughler JM, Pregenzer JF, Chase RL, Ducan LA, Jacobson EJ, McCall JM (1987) Novel 21-aminosteroids as potent inhibitors of iron-dependent lipid peroxidation. J Biol Chem 262: 10438–10440PubMedGoogle Scholar
  7. Bruenger FW, Stover BJ, Atherton DR (1967) The incorporation of various metal ions in vivo and in vitro produced melanin. Radiat Res 32: 1–12PubMedCrossRefGoogle Scholar
  8. Cohen G (1985) In: Lajtha A (ed) Handbook of neurochemistry, vol 4. Plenum Press, New York, pp 315–330Google Scholar
  9. Crichton RR (1979) Interaction between iron metabolism and oxygen activation. In: Oxygen free radicals and tissue damage. Ciba Foundation Symposium No 65 New Ser. Excerpta Medica, Amsterdam, pp 57–76Google Scholar
  10. D’Amato RJ, Lipman ZP, Snyder SH (1986) Selectivity of the Parkinson neurotoxin MPTP: toxic metabolite MPP + binds to neuromelanin. Science 231: 987–991PubMedCrossRefGoogle Scholar
  11. Dexter DT, Wells FR, Agid F, Agid Y, Lees AJ, Jenner P, Marsden CD (1989a) Increased nigral iron content in post-mortem parkinsonian brain. J Neurochem 52: 1830–1836CrossRefGoogle Scholar
  12. Dexter DT, Carter CJ, Wells FR, Javoy-Agid Y, Lees A, Marsden CD (1989b) Basal lipid peroxidation in substantia nigra is increased in Parkinson’s disease. J Neurochem 52: 381–389CrossRefGoogle Scholar
  13. Donaldson J, Barbeau A (1985) Managanese neurotoxicity: possible clues to aetiology of human brain disorders. In: Gabay S, Harris J, Ho BT (eds) Metal ions in neurology and psychiatry. Alan R Liss, New York, pp 259–285Google Scholar
  14. Drayer BP, Olanow W, Burger P, Johnson GA, Herfkens R, Riederer P (1986) Parkinson Plus syndrome: diagnosis using high field MR imaging of brain iron. Radiology 159: 493–498PubMedGoogle Scholar
  15. Earle KM (1968) Trace metals in parkinsonian brains. J Neuropathol Exp Neurol 27: 1–14PubMedCrossRefGoogle Scholar
  16. Fitzsimons DW (1979) Oxygen free radicals and tissue damage. Ciba Foundation Symposium No 65 New Ser. Excerpta Medica, AmsterdamCrossRefGoogle Scholar
  17. Hall ED (1988) Effects of the 21-aminosteroid 474006F on post-traumatic spinal cord ischaemia in cats. J Neurosurg 68: 462–465PubMedCrossRefGoogle Scholar
  18. Hall ED, Yonkers PA (1988) Attenuation of postischaemic cerebral hypoperfusion by the 21-aminosteroid 474006F. Stroke 19: 340–344PubMedCrossRefGoogle Scholar
  19. Halliwell B (1987) Oxidants and human disease: some new concepts. FASEB J 1: 358–364PubMedGoogle Scholar
  20. Halliwell B (1989) Oxidants and the central nervous system: some fundamental questions. Acta Neurol Scand (in press)Google Scholar
  21. Halliwell B, Grootveld M, Harparkash K, Fagerheim I (1988) Aromatic hydroxylation and uric acid degradation as methods for detecting and measuring oxygen radicals in vitro and in vivo. In: Rico-Evans C, Halliwell B (eds) Free radicals methodology and concepts. Richelieu Press, London, pp 33–59Google Scholar
  22. Halliwell B, Gutteridge JMC (1986) Oxygen free radicals and iron in relation to biology and medicine: some problems and concepts. Arch Biochem Biophys 246: 501–514PubMedCrossRefGoogle Scholar
  23. Halliwell B, Gutteridge JMC (1988) Oxygen radicals and the nervous system. Trends Neurosci 8: 22–26CrossRefGoogle Scholar
  24. Hill JM (1988) In: Youdim MBH (ed) Brain iron: neurochemical and behavioural aspects. Taylor and Francis, London, pp 1–24Google Scholar
  25. Hirsch E, Graybeil AM, Agid YA (1988) Melaninized dopaminergic neurons are differentially susceptible to degeneration in Parkinson’s disease. Nature 334: 345–348PubMedCrossRefGoogle Scholar
  26. Hornykiewicz O (1988) Neurochemical pathology and the etiology of Parkinson’s disease: basic facts and hypothetical possibilities. Mt Sinai J Med 55: 11–20PubMedGoogle Scholar
  27. Kinenuchi H, Fowler CJ, Tipton KF (1987) The neurotoxicity of 1-methyl4-phenyl-1,2,3,6-tetrahydropyridine ( MPTP) and its relevance to Parkinson’s disease. Neurochem Int 11: 359–373Google Scholar
  28. Kohen R, Chevion M (1986) Paraquat toxicity is enhanced by iron and reduced by desferrioxamine in laboratory mice. Biochem Pharmacol 34: 1841–1843CrossRefGoogle Scholar
  29. Konradi C, Riederer P, Youdim MBH (1986) Hydrogen peroxide enhances the activity of monoamine oxidase type B and not type A. A pilot study. J Neural Transm [Suppl] 22: 61–73Google Scholar
  30. Larsson B, Tjalve H (1979) Studies on the mechanism of drug binding to melanin. Biochem Pharmacol 28: 1181–1187PubMedCrossRefGoogle Scholar
  31. Liccione J J, Maines MD (1988) Selective vulnerability of glutathione metabolism and cellular defense mechanism in rat striatum to manganese. J Pharmacol Exp Ther 247: 156–161PubMedGoogle Scholar
  32. Mann DM, Yates PO (1983) Possible rate of neuromelanin in the pathogenesis of Parkinson’s disease. Mech Aging Dev 21: 193–203PubMedCrossRefGoogle Scholar
  33. Masson HS, Ingram D J, Allen B (1960) The free radical property of melanins. Arch Biochem Biophys 86: 225–230CrossRefGoogle Scholar
  34. Minotti G, Aust SD (1987) The requirement for iron (III) in the initiation of lipid peroxidation by iron ( II) and hydrogen peroxide. J Biol Chem 262: 1098–1104PubMedGoogle Scholar
  35. Perry TL, Young VN (1986) Idiopathic Parkinson’s disease, progressive supranuclear palsy and abnormal glutathione metabolism in the substantia nigra of patients. Neurosci Lett 67: 269–274PubMedCrossRefGoogle Scholar
  36. Peterson CM, Graziano JH, Grady RW, Jones RL, Cerami A (1974) Clinical evolution of 2,3-dihydroxybenzoic acid as an oral chelating drug. Am Soc Hematol 168: 101 (Abstract)Google Scholar
  37. Pilas B, Sana T, Kalyanaraman B, Swartz HM (1988) The effect of melanin on iron associated decomposition of hydrogen peroxide. Free Rad Biol Med 4: 285–293PubMedCrossRefGoogle Scholar
  38. Potts AM, Au PC (1976) The affinity of melanin for inorganic ions. Exp Eye Res 22: 487–491PubMedCrossRefGoogle Scholar
  39. Riederer P, Sofic E, Rausch WD, Schmidt B, Reynolds GP, Kellinger K, Youdim MBH (1989) Transition metals, ferritin, glutathione and ascorbic acid in parkinsonian brain. J Neurochem 52: 515–520PubMedCrossRefGoogle Scholar
  40. Riederer P, Youdim MBH (1987) MPTP-induced dopaminergic neurotoxicity. A useful model in the study of Parkinson’s disease? Neurochem Int 11: 379–381PubMedCrossRefGoogle Scholar
  41. Sofic E, Riederer P, Heinsen H, Beckmann H, Reynolds GP, Hebenstreit G, Youdim MBH (1988) Increased iron ( III) and total iron content in postmortem substantia nigra of parkinsonian brain. J Neural Transm 74: 199–205PubMedCrossRefGoogle Scholar
  42. Spina MB, Cohen G (1988) Exposure of school synaptosomes to L-dopa increases levels of oxidized gluathione. J Pharmacol Exp Ther 247: 502–507PubMedGoogle Scholar
  43. Spina MB, Cohen G (1989) Dopamine turnover and glutathione oxidation. Implications for Parkinson’s disease. Proc Natl Acad Sci USA 86: 1398–1400PubMedCrossRefGoogle Scholar
  44. Tanner CM (1989) The role of environmental toxins in the etiology of Parkinson’s disease. Trends Neurosci 12: 49–59PubMedCrossRefGoogle Scholar
  45. Triggs WJ, Willmore LJ (1984) In vivo lipid peroxidation in rat brain following intracortical Fe + + injection. J Neurochem 42: 976–980PubMedCrossRefGoogle Scholar
  46. Wilson RL (1979) Hydroxyl radicals and biological damage in vitro: what relevance to in vivo. In: Oxygen free radicals and tissue damage. Ciba Foundation Symposium No 65. New Ser. Excerpta Medica, Amsterdam, pp 19–42Google Scholar
  47. Yehuda S, Youdim MBH (1988) Brain iron deficiency: biochemistry and behaviour. In: Youdim MBH (ed) Brain iron neurochemical and behavioural aspects. Taylor and Francis, London, pp 89–114Google Scholar
  48. Youdim MBH (1985) Brain iron metabolism in relation to dopaminergic neurotransmission. In: Lajtha A (ed) Handbook of neurochemistry, vol 10. Plenum Press, New York, pp 731–735Google Scholar
  49. Youdim MBH (1988) Iron in the brain: implications for Parkinson’s and Alzheimer’s diseases. Mt Sinai J Med 55: 97–101PubMedGoogle Scholar
  50. Youdim MBH, Ben-Shachar D, Riederer P, Melamed E (1988) MPTP neurotoxicity and brain iron. In: MPTP-induced neurotoxicity Symposium, Cagliari (Abstract )Google Scholar
  51. Youdim MBH, Ben Shachar D, Riederer P (1989) Is Parkinson’s disease a progressive siderosis of substantia nigra resulting in iron and melanin induced neurodegeneration? Acta Neurol Scand (in press)Google Scholar

Copyright information

© Springer-Verlag/Wien 1990

Authors and Affiliations

  • M. B. H. Youdim
    • 1
  • D. Ben-Shachar
    • 1
  1. 1.Department of Pharmacology, TechnionRappaport Family Research InstituteHaifaIsrael

Personalised recommendations